TrialFrontiers in immunology2024

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study.

Na Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.